NCT00969306

Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients

Chloroquine as an Anti-autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients: A Phase 1 Trial

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Maastricht Radiation Oncology · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

Chloroquine might very well be able to increase overall survival in small cell lung cancer by sensitizing cells resistant to chemotherapy and radiotherapy.

Detailed description

Tumor hypoxia is a well-known factor negatively influencing outcome in many solid tumors, including small cell lung cancer. Hypoxic cells are more radio-resistant, more chemo-resistant and more prone to develop distant metastases than normoxic cells. One of the mechanisms responsible for survival of these therapy-resistant hypoxic cells is (macro-)autophagy: a phenomenon in which cells provide themselves with energy (ATP) by digesting their own cell-organelles. Chloroquine is a potent blocker of autophagy and has been demonstrated in a lab setting to dramatically enhance tumor response to radiotherapy, chemotherapy and even anti-hormonal therapy. Thus, chloroquine might very well be able to increase overall survival in small cell lung cancer by sensitizing cells resistant to chemotherapy and radiotherapy.

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Chloroquine, A-CQ 100	Administration: * Orally * Timing: Once daily * Tablets of 100 mg * During or after meals * In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose. * Patients should always note date and time of intake on the chloroquine monitoring form.

Timeline

• Start date: 2013-09-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2009-09-01
• Last updated: 2019-02-15

Locations

4 sites across 1 country: Netherlands